Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 3 , Pages 305-316 , June 2009

Diabetes and acute coronary syndromes

  • Marco Roffi, MD (Director)

      Affiliations

    • Corresponding Author InformationCorresponding author. Interventional Cardiology Unit, Division of Cardiology, University Hospital, Rue Micheli-du-Crest 24, 1211 Geneva, Switzerland. Tel.: +41 22 37 27 208; Fax: +44 22 37 27 229.
    • ,
  • Franz R. Eberli, MD (Professor, Chairman of Cardiology)

References 

  1. Bartnik M, Ryden L, Ferrari R, et al. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. European Heart Journal. 2004;25(21):1880–1890
  2. Bhatt DL, Roe MT, Peterson ED, et al. Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. The Journal of the American Medical Association. 2004;292(17):2096–2104
  3. Roe MT, Parsons LS, Pollack CV, et al. Quality of care by classification of myocardial infarction: treatment patterns for ST-segment elevation vs non-ST-segment elevation myocardial infarction. Archives of Internal Medicine. 2005;165(14):1630–1636
  4. Brogan GX, Peterson ED, Mulgund J, et al. Treatment disparities in the care of patients with and without diabetes presenting with non-ST-segment elevation acute coronary syndromes. Diabetes Care. 2006;29(1):9–14
  5. Malmberg K, Yusuf S, Gerstein HC, et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation. 2000;102(9):1014–1019
  6. Dotevall A, Hasdai D, Wallentin L, et al. Diabetes mellitus: clinical presentation and outcome in men and women with acute coronary syndromes. Data from the Euro Heart Survey ACS. Diabetic Medicine. 2005;22(11):1542–1550
  7. Otten R, Kline-Rogers E, Meier DJ, et al. Impact of pre-diabetic state on clinical outcomes in patients with acute coronary syndrome. Heart. 2005;91(11):1466–1468
  8. Mak KH, Moliterno DJ, Granger CB, et al. Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. Journal of the American College of Cardiology. 1997;30(1):171–179
  9. Zuanetti G, Latini R, Maggioni AP, et al. Influence of diabetes on mortality in acute myocardial infarction: data from the GISSI-2 study. Journal of the American College of Cardiology. 1993;22(7):1788–1794
  10. Norhammar A, Malmberg K, Ryden L, et al. Under utilisation of evidence-based treatment partially explains for the unfavourable prognosis in diabetic patients with acute myocardial infarction. European Heart Journal. 2003;24(9):838–844
  11. Kosiborod M, Rathore SS, Inzucchi SE, et al. Admission glucose and mortality in elderly patients hospitalized with acute myocardial infarction: implications for patients with and without recognized diabetes. Circulation. 2005;111(23):3078–3086
  12. Aguilar D, Solomon SD, Kober L, et al. Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. Circulation. 2004;110(12):1572–1578
  13. Levantesi G, Macchia A, Marfisi R, et al. Metabolic syndrome and risk of cardiovascular events after myocardial infarction. Journal of the American College of Cardiology. 2005;46(2):277–283
  14. Feit F, Manoukian SV, Ebrahimi R, et al. Safety and efficacy of bivalirudin monotherapy in patients with diabetes mellitus and acute coronary syndromes: a report from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. Journal of the American College of Cardiology. 2008;51(17):1645–1652
  15. Stuckey TD, Stone GW, Cox DA, et al. Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial). American Journal of Cardiology. 2005;95(1):1–7
  16. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. The New England Journal of Medicine. 2001;345(7):494–502
  17. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358(9281):527–533
  18. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366(9497):1607–1621
  19. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. The New England Journal of Medicine. 2005;352(12):1179–1189
  20. Sabatine MS, Cannon CP, Gibson CM, et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. The Journal of the American Medical Association. 2005;294(10):1224–1232
  21. Fateh-Moghadam S, Plockinger U, Cabeza N, et al. Prevalence of aspirin resistance in patients with type 2 diabetes. Acta Diabetologica. 2005;42(2):99–103
  22. Angiolillo DJ, Bernardo E, Ramirez C, et al. Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. Journal of the American College of Cardiology. 2006;48(2):298–304
  23. Roffi M, Chew D, Mukherjee D, et al. Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Gradient of benefit related to the revascularization strategy. European Heart Journal. 2002;23(18):1441–1448
  24. Roffi M, Chew DP, Mukherjee D, et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation. 2001;104(23):2767–2771
  25. Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. European Heart Journal. 2007;28(13):1598–1660
  26. Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. The New England Journal of Medicine. 2001;344(25):1895–1903
  27. Mahaffey KW, Cohen M, Garg J, et al. High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trial. The Journal of the American Medical Association. 2005;294(20):2594–2600
  28. Blazing MA, de Lemos JA, White HD, et al. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. The Journal of the American Medical Association. 2004;292(1):55–64
  29. Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. The New England Journal of Medicine. 2008;358(21):2218–2230
  30. Wallentin L, Lagerqvist B, Husted S, et al. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease. Lancet. 2000;356(9223):9–16
  31. Norhammar A, Malmberg K, Diderholm E, et al. Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization. Journal of the American College of Cardiology. 2004;43(4):585–591
  32. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. The New England Journal of Medicine. 2001;344(25):1879–1887
  33. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Lancet. 1994;343(8893):311–322
  34. Grines C, Patel A, Zijlstra F, et al. Primary coronary angioplasty compared with intravenous thrombolytic therapy for acute myocardial infarction: six-month follow up and analysis of individual patient data from randomized trials. American Heart Journal. 2003;145(1):47–57
  35. Bonnefoy E, Steg PG, Chabaud S, et al. Is primary angioplasty more effective than prehospital fibrinolysis in diabetics with acute myocardial infarction? Data from the CAPTIM randomized clinical trial. European Heart Journal. 2005;26(17):1712–1718
  36. Hsu LF, Mak KH, Lau KW, et al. Clinical outcomes of patients with diabetes mellitus and acute myocardial infarction treated with primary angioplasty or fibrinolysis. Heart. 2002;88(3):260–265
  37. Luscher TF, Steffel J, Eberli FR, et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation. 2007;115(8):1051–1058
  38. Stettler C, Allemann S, Wandel S, et al. Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. BMJ. 2008;337:a1331
  39. Kelbaek H, Thuesen L, Helqvist S, et al. Drug-eluting versus bare metal stents in patients with st-segment-elevation myocardial infarction: eight-month follow-up in the Drug Elution and Distal Protection in Acute Myocardial Infarction (DEDICATION) trial. Circulation. 2008;118(11):1155–1162
  40. Mauri L, Silbaugh TS, Garg P, et al. Drug-eluting or bare-metal stents for acute myocardial infarction. The New England Journal of Medicine. 2008;359(13):1330–1342
  41. Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ. 1997;314(7093):1512–1515
  42. Malmberg K, Ryden L, Wedel H, et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. European Heart Journal. 2005;26(7):650–661
  43. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. The New England Journal of Medicine. 2008;358(24):2545–2559
  44. Peterson ED, Pollack CV, Roe MT, et al. Early use of glycoprotein IIb/IIIa inhibitors in non-ST-elevation acute myocardial infarction: observations from the National Registry of Myocardial Infarction 4. Journal of the American College of Cardiology. 2003;42(1):45–53
  45. Wiviott SD, Braunwald E, Angiolillo DJ, et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation. 2008;118(16):1626–1636

PII: S1521-690X(09)00004-9

doi: 10.1016/j.beem.2009.01.003

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 3 , Pages 305-316 , June 2009

Article Tools

* Image Usage & Resolution